Key takeaways:
- FDA has told the White House it plans to publish a proposed rule in December 2026 that would require companies to notify the agency before using an ingredient under GRAS status. Right now, that notification is voluntary.
- The proposal would presume any non-notified ingredient use is not GRAS, effectively ending the self-affirmation pathway most mid-market manufacturers rely on today.
- December 2026 isn’t a compliance deadline. It’s when the comment period opens, and the FDA’s timeline puts a final rule two to three years out. The real deadline is getting your ingredient file audit-ready before that window closes.
The FDA has scheduled a proposed rule for December 2026 that would require a GRAS notice before you can use an ingredient under Generally Recognized as Safe (GRAS) status. Right now, you don’t have to tell the FDA anything. You determine an ingredient is safe, document it, and use it. The FDA’s proposal would flip that. A use the agency hasn’t been notified about would be presumed not GRAS, treated the same as an unapproved food additive.
This has been coming since March 2025, when HHS Secretary Robert F. Kennedy Jr. directed FDA to explore eliminating the self-affirmed GRAS pathway entirely. The rule has already slipped once, from an original October 2025 target. The most recent Unified Agenda update, released July 3, 2026, puts the proposed rule’s publication in December, tracked under RIN 0910-AJ02 and classified “economically significant,” meaning the Office of Management and Budget expects it to affect the economy by at least $100 million a year.
What the rule would require of food companies
The proposal would amend 21 CFR Parts 170 and 570 to require a GRAS notice for food and animal-food substances a company intends to market as GRAS. The FDA would maintain a public inventory of notified uses and define, more clearly than it does today, how it determines a use is not GRAS. Substances already listed or affirmed by regulation, or ones that already have an FDA “no questions” letter on file, would stay exempt.
The scope has narrowed as the rule has moved through drafting. Earlier versions reportedly covered indirect additives, including food-contact materials; the current agenda entry limits itself to “certain uses of food substances.” However, that narrower language sits next to an FDA statement that it wants notices for “all new substances claimed to be GRAS.” Until the actual text publishes, the scope stays unsettled.
The agenda references “streamlined submissions” and a “limited submission window” for substances already on the market before the rule takes effect. That suggests companies with existing self-affirmed conclusions will get a defined, time-boxed way to bring them into the new system on lighter terms, instead of starting from zero. No one outside the FDA knows yet how long that window will run or what it will demand. That’s precisely why the audit has to happen on your timeline, ahead of the window, rather than scrambling once it opens.
Why December isn’t your real deadline
In December, the FDA publishes a proposed rule, not a final one. A public comment period follows, typically 60 to 120 days, and food industry rulemakings of this size routinely draw thousands of comments for the FDA to work through. It’s estimated that a final rule will arrive no earlier than late 2028 or 2029, before litigation even starts. The FDA told Congress back in 2016 that it lacked express statutory authority for mandatory notification. Post-Chevron, courts owe the agency’s reading of the statute no deference, and Congress had a chance to require notification when it legislated on food-contact substances and chose not to. A legal challenge here is close to certain.
That timeline changes why you’re doing this, not what you should do. The race is toward the moment the streamlined window opens, whenever the final rule sets it, not toward December. That window is the cheapest way through this transition, and it won’t stay open long.
What to inventory before the window opens
Three things, in order:
- Know what you’re running on self-affirmation. Most GRAS review programs at mid-size manufacturers were built ingredient by ingredient over years, often by different people, with no single list of which conclusions were self-affirmed versus FDA-notified. Build that list first. You can’t gap-assess a file you can’t locate.
- Check whether your documentation would clear the FDA’s bar today. A GRAS notice has to include the same quality and quantity of safety data as a food additive petition: identity and manufacturing specifications, exposure estimates under intended use, and current safety literature, not what was current when the file was built. If your dossier hasn’t been touched since the original determination, assume it has gaps.
- Decide which legacy conclusions are worth notifying now versus waiting on. Regulatory consultants advise clients to consider filing an FDA-notified GRAS conclusion voluntarily, ahead of any mandate, on the logic that certainty today costs less than certainty under a compressed transition window later. But keep in mind that notifying early means disclosing ingredient identity, manufacturing detail, and exposure data publicly, since GRAS notice content can’t be kept confidential.
Most regulatory affairs teams at mid-market manufacturers weren’t staffed for the scale this audit requires: matching specs and safety literature against FDA’s notice checklist, plant by plant, SKU by SKU, ingredient by ingredient. It’s structured, repetitive comparison work, which is exactly the kind of job AI-assisted document review can speed up. The judgment on what to file, and when, still belongs to your regulatory team. The document matching that used to eat weeks doesn’t have to anymore.
The bet you’re making if you wait
If you wait for the proposed text to publish in December before starting, you’ll be running your audit during the loudest, most contested phase of this rulemaking, competing with every other manufacturer’s regulatory affairs team for the same outside counsel and consultants. If you start the inventory now, you’re deciding what a defensible ingredient file looks like on your own schedule instead of FDA’s, and you’re in position to move the moment the streamlined window opens.
